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Background: Chediak-Higashi Syndrome (CHS) is a rare autosomal recessive disease characterized by immunodeficiency,
oculocutaneous albinism, neurological dysfunction, and early death. Individuals with CHS present with increased
susceptibility to infections of the skin, upper-respiratory tract, gastrointestinal tract, and oral tissues. Classical CHS is
caused by mutations in the gene encoding lysosomal trafficking regulator (LYST). Although defects in cytotoxic T
cell lytic secretory granule secretion and neutrophil phagocytosis are suggested to contribute to the immunodeficiency
in CHS, the underlying molecular mechanisms are unknown. We hypothesized that skin fibroblasts from CHS subjects
exhibit impaired immune response due to defective trafficking of inflammatory factors.
Methods and results: Primary skin fibroblasts from CHS subjects or healthy controls were assessed for genes encoding
inflammatory response factors using PCR array. At baseline, we found CD14, IL1R1 and TLR-1 were down-regulated
significantly (≥2 fold change) and the genes encoding TLR-3, IL-1β and IL-6 were up-regulated in CHS cells compared to
control cells. When challenged with E. coli lipopolysaccharide (LPS), CHS cells were less responsive than control cells,
with only 8 genes significantly up-regulated (3–68 fold change) compared to baseline values, whereas 28 genes in
control cells were significantly up-regulated at a much higher magnitude (3–4,629 fold change). In addition, 50%
of the genes significantly up-regulated in LPS-treated control cells were significantly lower in LPS-treated CHS cells.
IL-6, a fibroblast-derived proinflammatory cytokine essential for fighting infections was significantly lower in culture
media of CHS cells with or without LPS. Furthermore, Western blot and immunofluorescent staining revealed that TLR-2
and TLR-4 were diminished on cell membranes of CHS cells and dissociated from Rab11a.
Conclusions: For the first time, results from our study indicate defective trafficking of TLR-2 and TLR-4 contributes to
the hyposensitive response of CHS skin fibroblasts to immunogenic challenge, providing a potential therapeutic target
for clinical intervention in CHS.
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Chediak-Higashi syndrome (CHS; OMIM# 214500) is a
rare autosomal recessive disease characterized by partial
oculocutaneous albinism (OCA), immunodeficiency, mild
bleeding tendency, and varying neurologic problems [1,2].
Among CHS individuals, approximately 15% develop a
milder form of the disease exhibiting an atypical pheno-
type, while the remaining 85% develop the more severe
classic form of the syndrome at birth or soon after
birth. It has been reported that individuals with clas-
sical CHS present persistent and recurrent infections
in skin, upper-respiratory tract, gastrointestinal tract,
and oral tissues [3,4]. Individuals with classical CHS
often develop the “accelerated phase”, characterized by
lymphoproliferative infiltration of the bone marrow
and reticuloendothelial system, that is usually fatal
unless treated by immunosuppression and bone mar-
row transplantation (BMT) [1,2,5].
The hallmark diagnostic feature of CHS is the presence
of giant inclusions due to fusion of cytoplasmic granules
in many cell types, including hematopoietic cells, renal
tubular cells, neurons, melanocytes, and fibroblasts [1,6].
At the molecular level, the disease is caused by mutations
in the lysosomal trafficking regulator gene (LYST, also
known as CHS1) on 1q42.1-q42.2, identified after the
murine homologue gene beige was discovered [7]. Studies
suggest a role for LYST in vesicle formation and transport
of proteins, though its dysfunction in the context of CHS
is not completely understood [1,2]. Results from studies
led to the suggestion that the enlarged lysosomes found in
CHS cells result from abnormalities in membrane fusion
[8] or fission [9], which could occur during the biogenesis
of the lysosomes.
The deficiency in intracellular transport of vesicles leads
to a generalized immunodeficiency in mice and humans
[10,11]. Increased susceptibility to infection presented by
individuals with CHS is known to be a consequence of
impaired secretion of lytic secretory granules by cyto-
toxic T cells and defective phagocytosis, and chemotaxis
by neutrophils [9,12,13]. However, other than the pro-
fessional immune cells, fibroblasts, as active contribu-
tors to the regulation of the inflammatory response,
provide the first barrier against pathogens [14-16]. As
BMT only restores the hematopoietic stem cells but
cannot correct the mutation in somatic cells such as
skin and gingival fibroblasts, it is important to under-
stand whether LYST dysfunction affects immune-
inflammatory functions of fibroblasts.
Toll-like receptors (TLRs) act as essential sensors of
pathogen-associated molecular patterns, ranging from
lipopeptides to nucleic acids [17]. For example, E. coli
lipopolysaccharide (LPS) bound to CD14 and MD-2 is
recognized by TLR-4, controlling the expression of
genes encoding several inflammatory mediators, includingcyclooxygenase-2 (COX-2), and pro-inflammatory cytokines
such as interleukin (IL)-1β and −6 [18]. Biological availability
of TLRs has been reported to be dependent on lyso-
somal function, underscoring the importance of a nor-
mal lysosomal distribution for a balanced TLR response
system [19]. Localization and trafficking of TLRs is
essential for pathogen recognition, downstream signal-
ing activation and modulation [19-22].
The aims of this in vitro study were to determine how
CHS affects the immune response of skin fibroblasts and
to define the mechanisms by which disturbed intracel-
lular trafficking leads to impaired immune responses
observed in individuals with CHS. We hypothesized that
primary skin fibroblasts obtained from individuals with
CHS would exhibit a hyposensitive response to immuno-
genic challenge.
Methods
Cell isolation, culture and treatment
A total of three subjects with classic CHS were en-
rolled in the Institutional Review Board approval
(NIH/NHGRI - protocol #00-HG-0153) study (Table 1).
Primary skin fibroblasts were obtained from these indi-
viduals with CHS. Briefly, a forearm skin biopsy was
obtained under local anesthesia and enzymatically
digested with 0.25% trypsin-EDTA solution (Invitrogen,
CA, USA) for 1 hour at 37°C. Cells were maintained in
Dulbecco's modified Eagle medium (DMEM) with 10%
fetal bovine serum (FBS), 1% L-glutamine, and 1% peni-
cillin/streptomycin (Gibco BRL) and incubated at 37°C
in a 5% CO2 atmosphere. For the control group, cells
were purchased from American Type Culture Collec-
tion (VA, USA), and stored in liquid nitrogen until use.
Cells from passages 2 to 8 were used for all experi-
ments. Twenty-four hours after plating, growth medium
was changed to DMEM with 5% FBS (and penicillin,
streptomycin, and L-glutamine). For baseline data, cells
were cultured without E.coli LPS and for LPS challenge
assay, cells were cultured and treated with LPS at 10 ng/mL
for 3 hrs.
Gene expression analysis
For gene expression analysis, total RNA was obtained
from cells in vitro using the RNeasy Micro kit (Qiagen,
CA, USA), cDNA was synthesized by using the RT2 First
Strand Kit (Qiagen), and samples were analyzed for expres-
sion of 84 genes involved in immune-inflammatory regula-
tion by a PCR array platform (PAHS-077Z, SABioscience/
Qiagen). PCR array reactions were performed with the
LightCycler 480 system (Roche Diagnostics, IN, USA)
following the manufacturer's recommendations. Real time
quantitative PCR (RT-qPCR) was performed as described
before [23]. Primer sequences used in RT-qPCR are shown
in Table 2.
Table 1 Genotypes of the CHS patients
Patients Phenotype Genotype
Mutation Mutation type
CHS 4 Classic c.1540C > T; p.R514X (exon 5) c.9893delT; p.F3298fsX3304 (exon 43) Nonsense/Frameshift
CHS 13 Classic c.4322_4325delAGAG;p.E1441VfsX11 (exon 12) c.4353G > A; p.W1451X (exon12) Frameshift/Nonsense
CHS 21 Classic c.10883dupA; p.Y3628X (exon 49) c.10883dupA; p.Y3628X (exon 49) Nonsense/Nonsense
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For protein analysis, total cellular proteins were extracted
from cells using a lysis and extraction kit (Thermo
Scientific, MA, USA) following the manufacturer's
recommendations. EDTA-free Halt™ protease inhibitor
cocktail (Thermo Scientific) was included to prevent pro-
tein degradation during the extraction process. Protein
concentration was determined by the Bradford colorimet-
ric assay (Thermo Scientific).
SDS-PAGE and Western blotting were performed as
described previously [23]. Primary antibodies against TLR-
2 (Abcam, MA, USA), TLR-4 (Abcam), GAPDH (Abcam),
and IRDye employed with secondary antibodies (LI-COR
Biosciences, NE, USA) were used to detect proteins of
interest. Detection was performed using a digital imaging
system (ODYSSEY CLx-LI-COR), and digital files were
analyzed with Image Studio Software (LI-COR).
Immunofluorescence and membrane staining
Skin fibroblasts from both control and CHS subjects
were grown on 4-well chamber slides for 24 hrs, then
fixed with 4% paraformaldehyde (PFA), permeabilized
using 0.1% triton-X-100, and incubated overnight at 4°C
with rabbit anti-TLR-2 (Abcam), mouse anti-TLR-4
(Abcam), mouse anti-Rab11a (BD Biosciences, CA, USA),
and rabbit anti-Rab11a antibodies (Cell Signaling Tech-
nology, MA, USA). Donkey anti-mouse or anti-rabbit
Alexafluor-488 or −555 conjugated antibodies (Invitrogen,
CA, USA) were used as secondary antibodies. The slides
were mounted in ProLong Gold anti-fade reagent with
DAPI (Invitrogen) and imaged using a Zeiss 510 META
confocal laser-scanning microscope with the pinhole set
to 1 Airy unit (Carl Zeiss, NY, USA). A series of opticalTable 2 Real-time PCR primer sequences







GAPDH NM_002046.4 AGCCACATCGCTsections were collected from the xy plane and merged into
maximum projection images. For membrane staining of
TLR-2 and TLR-4, cells were seeded as above and allowed
to attach for 24 hrs, then cooled to 4°C and incubated for
1 hour with rabbit polyclonal antibodies against TLR-2 or
mouse monoclonal antibodies against TLR-4 diluted in
DMEM. Cells were washed twice for 5 minutes with ice
cold PBS to remove unbound antibody, and fixed using
4% PFA for an additional 30 minutes at 4°C, and for a fur-
ther 30 minutes at room temperature. The slides were
then processed for immunofluorescence staining as above,
using donkey anti-mouse or anti-rabbit Alexafluor-488
conjugated secondary antibodies (Invitrogen). Slides were
mounted and imaged as above.
Statistical analysis
Experiments were performed in triplicate and repeated
at least twice. Values are given as means and standard
deviations, or as fold-change. An integrated web-based
software RT2 Profiler PCR array software package
(SABiosciences) was used for PCR array data analysis. In
general, the normality of the data is analyzed and the
p values are calculated based on a Student’s t-test of
the replicate 2 (−ΔCt) values for each gene in the control
group and treatment groups. Student's t-test (α = 0.05)
was performed for analyzing RT-qPCR data. One-way
ANOVA with Tukey’s post hoc test were used for quan-
titation of Western blot and ELISA. Correlation analysis
was performed by Pearson product moment correlation
co-efficient analyses with two-tailed 95% confidence. Statis-
tical analyses were carried out using GraphPad Prism soft-
ware version 6 (GraphPad Software, CA, USA) and RT2
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CHS skin fibroblasts in vitro exhibit hyperactive immune
activity at baseline
To determine how CHS affects expression of genes asso-
ciated with inflammation and immune response, expres-
sion profiles of skin fibroblasts at baseline were screened
by PCR array and RT-qPCR. PCR array revealed that
CD14, IL-1R1 and TLR-1 were significantly (p < 0.05)
down-regulated, with more than a 2-fold change in CHS
cells compared to control cells (Figure 1A, Table 3).
Furthermore, PCR array identified decreased TLR-2
and −4 expression (8- and 4-fold, respectively), and 4-
fold increased TLR-3 expression in CHS skin fibroblasts
compared to control cells, although without significance
(Figure 1A, Table 3). RT-qPCR confirmed statistically
significant 4-fold down regulation of TLR-4 in CHS cells
vs. controls (Figure 1B), while also reconfirming the
expression pattern for TLR-2 (3-fold decrease) and TLR-3
(2-fold increase) (Figure 1B and C).
RT-qPCR analysis revealed that in CHS fibroblasts,
IL-6 was significantly up-regulated (14-fold), and IL-1β
was up-regulated (15-fold) with a p-value close to 0.05
(Figure 1D). Furthermore, expression of cyclooxygenase
2 (COX-2), an enzyme largely responsible for inducing
inflammation, was significantly (p < 0.01) elevated (16-fold)
in CHS skin fibroblasts compared to control cells. Correl-
ation analysis shown in Table 4 indicated that expressionFigure 1 Immune activity is hyperactive in CHS skin fibroblasts at bas
inflammation-related factors between CHS cells and control cells (Ctrl) at base
(p-value) and X-axis shows the values of Log2 (fold change of CHS vs. control
more than 2-fold and green circles fall to the left of the green line represents
genes with changes of statistically significantly differences (p < 0.05 by t-test).
(p < 0.05) down-regulated with 2 to 3 fold changes. RT-qPCR data reveals that
TLR-2 and −4 are down-regulated in CHS cells at baseline; C. TLR-3 gene e
encoding IL1β and IL-6 are up-regulated in CHS cells at baseline; E. COX-2
were done twice, in triplicate, with comparable results. Statistically differeof COX-2, IL-6, and IL-1β were significantly and positively
correlated with one another as well as with TLR-3 gene
expression, while significantly and negatively correlated
with TLR-4 gene expression. Notably, TLR-2 gene ex-
pression was not significantly correlated with any of the
genes included in Table 4.
CHS skin fibroblasts exhibit a hyposensitive immune
response when challenged with LPS
Next we examined how mutations in LYST affect inflam-
mation and immune response genes of interest (identi-
fied in the preceding section and Figure 1) in skin
fibroblasts challenged with E. coli LPS. The PCR array
revealed that compared to LPS-treated control cells, 14
genes in CHS cells were either decreased significantly or
in a declining trend (Figure 2A green circles and Table 5).
This global trend indicated that, under LPS challenge,
the immune response was repressed in skin fibroblasts
of individuals with CHS. Notably, challenged CHS cells
exhibited 30-fold lower and 4-fold lower expression of
TLR-2 and −4, respectively, compared to challenged
control cells (Table 5). Only one gene (LY98) encoding
MD-2, the LPS recognition partner of TLR-4, was sig-
nificantly enhanced (2.5-fold) in CHS cells challenged
by LPS (Figure 2A and Table 5).
The observation that CHS cells exhibited an overall
lower level of immunogenic expression when comparedeline. A. The differences in the expression of genes encoding 84
line are shown volcano plot. Y-axis shows the values of minus Log10
). Red circles fall to the right of the red line represent genes increases
genes decreases more than 2 fold. Circles above the blue line represent
Three genes, TLR-1, IL-1R1 and CD14 (listed in Table 3) are significantly
compared to control cells at baseline: B. Expression of genes encoding
xpression is enhanced in CHS cells at baseline. D. Expression of genes
gene expression is up-regulated in CHS cells at baseline. Experiments
nces were accessed by a student’s t test (*p < 0.05 and **p < 0.01).
Table 3 Gene expression profile of untreated CHS cells compared to untreated control cells
Gene symbol Gene full name Fold regulation p-value
TLR1 Toll-like receptor 1 −3.25 0.00
CD14 CD14 molecule −3.14 0.01
IL1R1 Interleukin 1 receptor, type I −2.19 0.02
TLR2 Toll-like receptor 2 −8.04 0.06
TLR4 Toll-like receptor 4 −4.37 0.15
IL-6 Interleukin 6 2.50 0.18
IL-1β Interleukin 1β 9.21 0.30
TLR-3 Toll-like receptor 3 4.03 0.31
Note: Table 3 corresponds to the volcano plot of Figure 1A. Genes above the dotted line have altered expression in CHS cells with statistical significance (p < 0.05);
Genes below the dotted line were evaluated by RT-qPCR.
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cells decreased the expression of those specific factors,
as shown in Table 5. By comparing stimulated cells to
unstimulated cells, we revealed that both CHS and con-
trol cells exhibited increased expression of those specific
factors in response to LPS challenge, but CHS cells
exhibited a lower fold-response. As shown in Figure 2,
only 8 genes were significantly up regulated more than
2-fold (ranging from 2.45- to 75.76-fold) in LPS-treated
CHS cells compared to untreated CHS cells (Figure 2B
and Table 6). In contrast, LPS-treated control cells ex-
hibit significant up-regulation of 28 genes, more than
2-fold (ranging from 3- to 2,048-fold) compared to un-
treated control cells (Figure 2C and Table 7). Notably,
LPS treatment significantly enhanced expression of TLR-
2 and −4 in control cells, but not in CHS cells. Consist-
ent with trends in the PCR array data in Figure 2A,
LPS-treated CHS cells featured significantly lower mag-
nitude of IL-1β, IL-6 and COX-2 induction (40–200 fold)
compared to LPS-treated control cells (Figure 2D).
IL-6 is a proinflammatory cytokine that is secreted by
fibroblasts [24]. Secreted IL-6 protein in tissue culture
media was measured in LPS-treated and untreated
cells. The concentration of IL-6 was significantly lower
in medium from CHS cells compared to control cells
(Figure 2E). Additionally, exposure to LPS failed to
induce increased IL-6 secretion in CHS cells, while
LPS-treated control cells exhibited a significant 4-fold
increase in IL-6. The contradictory observation of
increased IL-6 gene expression and the decreasedTable 4 Summary of correlation between expression of indica
Correlation TLR-3 COX-2 IL-6
TLR-3 n/a r = +0.882; p < 0.05 r = +0.
COX-2 # n/a n.s.
IL-6 # n.s. n/a
IL-1β # # #
Note: 1. TLR-2 gene expression is not significantly correlated with any of the genes
moment correlation co-efficient analyses. Pearson r represents the correlation coeff
negative correlation. The significance is indicated by p value with two-tailed 95% csecretion of IL-6 protein in cell culture of CHS skin
fibroblasts suggests a defect in IL-6 secretion is related
to LYST mutations. Notably, the difference in secreted
IL-6 expression between controls and CHS fibroblasts
could partly arise from the source and culturing methods
of control and CHS cells. However, both control and CHS
cells were cultured under identical conditions in-house
and passaged several times before use in experiments,
nullifying any a priori differences.
CHS skin fibroblasts exhibit diminished protein
expression of TLR-2 and −4
Toll-like receptors are recognized as playing key roles in
innate immune response to immunogenic challenges,
such as microbial products including LPS [17]. Lower
gene expression of TLR-2 and TLR-4 in CHS fibroblasts
compared to controls cells (Figure 1A and B) prompted
us to analyze protein expression and localization to fur-
ther define the mechanism for the observed defective
immune response in CHS cells. At baseline, membrane-
bound TLR-2 and −4 were decreased markedly in CHS
versus control cells (Figure 3A-a, b and 3B-i, j), with
significant differences confirmed by quantitative analysis
of Western blot data (Figure 3C and E).
Cells were permeabilized to visualize cytosolic TLR-2
and −4, revealing that compared to robust cytosolic
TLR-2 in control fibroblasts, cytosolic TLR-2 was not
detectable in CHS cells (Figure 3A-f vs. c). Quantitative
analysis of Western blot confirmed this observation
(Figure 3D). In contrast, cytosolic TLR-4 was comparableted genes
IL-1β TLR-4
857; p < 0.05 r = +0.978; p < 0.001 n.s.
r = +0.884; p < 0.05 r = −0.911; p < 0.05
r = +0.829; p < 0.05 r = −0.821; p < 0.05
n/a r = −0.831; p < 0.05
shown in the table. 2. Correlation analysis was performed by Pearson product
iciency where 1 is total positive correlation, 0 is no correlation, and −1 is total
onfidence. n/a: not available; n.s.: not significant. #: redundant.
Figure 2 Skin fibroblasts from individuals with CHS exhibit a hyposensitive immune response when challenged with LPS. The differences in
the expression of genes encoding 84 inflammation-related factors are shown via volcano plots (A-C). Y-axis shows the values of minus Log10 (p-value)
and X-axis shows the values of Log2 (Fold change of CHS vs. control). Red circles fall to the right of the red line represent genes increases more than
2-fold and green circles fall to the left of the green line represents genes decreases more than 2 fold. Circles above the blue line represent
genes with changes of statistically significantly differences (p < 0.05 by t-test). A. Expression of genes encoding inflammation-related factors are
repressed significantly in LPS-treated CHS cells compared to LPS-treated control (Ctrl) cells (shown in Table 5). B. Only 8 genes (shown in Table 6)
are up-regulated significantly in LPS treated CHS cells compared to untreated CHS cells. C. 28 genes (shown in Table 7) are up-regulated
significantly in LPS-treated control cells compared to untreated control cells. D. RT-qPCR data reveals that when normalized to their respective
untreated cells, LPS-treated CHS cells exhibit significantly lower expression of genes encoding IL-6, IL-1β and COX-2 compared to LPS-treated control
cells. E. IL-6 expression in cell culture media evaluated by ELISA shows that IL-6 is significantly lower in culture media of CHS cells treated with or
without LPS. Experiments were done twice, in triplicate, with comparable results. Statistically differences were accessed by a student’s t test in panel D
(**p < 0.01 and ***p < 0.001) and by one-way ANOVA with Tukey’s post hoc test in panel E (*p < 0.05).
Table 5 Gene expression profile of LPS-treated CHS cells compared to LPS-treated control cells
Gene symbol Gene full name Fold regulation p-value
TLR2 Toll-like receptor 2 −30.20 0.02
IL1A Interleukin 1, alpha −7.85 0.01
LTB Lymphotoxin beta (TNF superfamily, member 3) −5.80 0.02
IL23A Interleukin 23, alpha subunit p19 −5.67 0.01
TLR4 Toll-like receptor 4 −4.03 0.01
CCL7 Chemokine (C-C motif) ligand 7 −3.78 0.00
CXCL3 Chemokine (C-X-C motif) ligand 3 −3.66 0.02
CXCR2 Chemokine (C-X-C motif) receptor 2 −3.55 0.02
TLR1 Toll-like receptor 1 −3.31 0.01
IL15 Interleukin 15 −3.23 0.00
CCR1 Chemokine (C-C motif) receptor 1 −2.91 0.03
IL18 Interleukin 18 −2.49 0.00
IL10 Interleukin 10 −2.20 0.05
IL1R1 Interleukin 1 receptor, type I −2.02 0.01
LY96* Lymphocyte antigen 96 (MD-2) 2.49 0.01
Note: Table 5 corresponds to the volcano plot of Figure 2A. * LY96, also known as MD-2, was the only gene significantly up-regulated in LPS treated CHS cells.
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Table 6 Gene expression profile of LPS-treated CHS cells compared to untreated CHS cells
Gene symbol Gene full name Fold regulation p-value
CXCL2 Chemokine (C-X-C motif) ligand 2 75.76 0.04
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)
68.75 0.03
IL8 Interleukin 8 68.59 0.03
CCL7 Chemokine (C-C motif) ligand 7 17.88 0.00
IL1A Interleukin 1, alpha 13.09 0.00
CXCL6 Chemokine (C-X-C motif) ligand 6 11.50 0.01
CCL4 Chemokine (C-C motif) ligand 4 7.53 0.00
C3AR1 Complement component 3a receptor 1 2.45 0.03
Note: Table 6 corresponds to the volcano plot in Figure 2B.
Table 7 Gene expression profile of LPS-treated control cells compared to untreated control cells
Gene symbol Gene full name Fold regulation p-value
CXCL3 Chemokine (C-X-C motif) ligand 3 2048.00 0.00
CCL5 Chemokine (C-C motif) ligand 5 1722.16 0.01
TNF Tumor necrosis factor 1652.00 0.02
IL1B Interleukin 1, beta 1573.76 0.00
IL8 Interleukin 8 658.63 0.00
CXCL2 Chemokine (C-X-C motif) ligand 2 633.27 0.00
CXCL1 Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity, alpha)
557.70 0.00
IL6 Interleukin 6 (interferon, beta 2) 450.90 0.01
SELE Selectin E 257.78 0.02
PTGS2 Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase)
206.98 0.01
CCL2 Chemokine (C-C motif) ligand 2 197.18 0.00
IL1A Interleukin 1, alpha 141.04 0.00
IL23A Interleukin 23, alpha subunit p19 61.53 0.00
CCL7 Chemokine (C-C motif) ligand 7 36.50 0.00
RIPK2 Receptor-interacting serine-threonine kinase 2 10.78 0.00
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 9.32 0.00
LTB Lymphotoxin beta (TNF superfamily, member 3) 7.82 0.01
CCL13 Chemokine (C-C motif) ligand 13 7.26 0.01
IL15 Interleukin 15 6.74 0.00
TLR2 Toll-like receptor 2 6.02 0.03
CSF1 Colony stimulating factor 1 (macrophage) 5.76 0.00
TLR7 Toll-like receptor 7 3.20 0.05
IL10 Interleukin 10 3.20 0.00
BCL6 B-cell CLL/lymphoma 6 3.13 0.00
TLR4 Toll-like receptor 4 2.81 0.00
CD40 CD40 molecule, TNF receptor superfamily member 5 2.53 0.00
IL18 Interleukin 1 2.39 0.03
TLR3 Toll-like receptor 3 2.36 0.03
Note: Table 7 corresponds to the volcano plot of Figure 2C.
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Figure 3 Skin fibroblasts from individuals with CHS exhibit diminished protein expression of TLR-2 and −4. A-B. Representative
microscopy images of fibroblasts from control and a CHS patient stained for TLR-2 and TLR-4. A. The protein expression of TLR-2 on the plasma
membrane in CHS cells is clearly reduced compared to control cells (b vs. a). Staining in permeabilized cells shows that there is still very little
signal seen in CHS patient cells, suggesting that TLR-2 is being mis-trafficked and degraded in these cells (f-h). In control cells there is co-localization
of TLR-2 and Rab11a shown as yellow in the merged image (c-e). B. Similar to TLR-2, the amount of TLR-4 on the plasma membrane in CHS cells is
significantly reduced compared to control cells (j vs. i). Staining in permeabilized cells shows that there is a noticeable reduction in signal in CHS cells
(n). In control cells there is co-localization of TLR-4 and Rab11a (m), but very little co-localization can be seen in CHS cells (p). Inserts are
enlarged images of area inside dashed boxes. Scale bar represents 20 mm. C-F. Quantitative analysis of Western blot result shows the expression of
TLR-4 and −2 of cells, treated with or without LPS. Experiments were done twice, in triplicate, with comparable results. Statistically differences were
accessed by one-way ANOVA with Tukey’s post hoc test in panel E (*p < 0.05, **p < 0.01 and ***p < 0.001).
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blot analysis confirmed this observation (Figure 3F).
The Rab11a GTPase has been shown to be involved in
the recycling and trafficking of TLRs [20]; therefore we
co-stained Rab11a with TLR-2 and −4. In control fibro-
blasts, Rab11a co-localized with TLR-2 and −4 (Figure 3,
A-e and B-m). However, in CHS cells, Rab11a localization
was notable for a lack of co-localization with TLR-4
(Figure 3B-p). Furthermore, Western blot revealed that
when challenged by LPS, CHS cells exhibited signifi-
cantly lower expression of TLR-2 compared to control
cells (Figure 3C and D). Although intracellular TLR-4
expression in CHS cells was similar to that of control
cells, the expression of membrane bound TLR-4 was
significantly decreased in CHS cells (Figure 3E and F).Discussion
Individuals with CHS are reported to exhibit increased
susceptibility to infections in tissues that act as barriers
to pathogenic invasion, such as the skin and gingiva
[3,4]. Fibroblasts, the major cells residing in skin and
gingiva, are immune competent cells that participate in
signaling and triggering an innate immunity reaction in
response to pathogens [24,25]. While CHS-induced defects
have been studied in major immune cell classes, including
neutrophils [26,27], macrophages [28], and T cells [29],
little is known about how mutations causing CHS affect
immunogenic responsiveness of fibroblasts. In these
in vitro studies of skin fibroblasts obtained from individ-
uals with CHS, we demonstrate hyperactive inflammatory
immune activity at baseline, yet hyporesponsiveness to
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expression and disturbed trafficking of TLR-2 and −4.
Our results demonstrate that at baseline (i.e. unstimu-
lated), CHS fibroblasts present hyperactive expression
of immune-related factors including IL-1β, IL-6, and
COX-2, compared to cells obtained from normal sub-
jects. Enhanced expression of these factors was signifi-
cantly and positively correlated with one another and
with enhanced TLR-3 expression in CHS cells, suggest-
ing co-regulation by common upstream signals. In fact,
TLR-3 is one of the upstream regulators that has been
shown to induce expression of the elevated immune-
related factors mentioned above (Figure 1D) [30]. Although
TLR-1, −2, −4, and CD14 were all decreased in CHS
cells, increased expression of TLR-3 may lead to the
mild hyperactive immune activity. The marked func-
tional difference between TLR-2 or −4, and TLR-3, is
that TLR-2 and −4 localize to the cell surface in order
to recognize foreign lipid structures, and rely on intra-
cellular trafficking to signal and replenish the surface
pool of TLR proteins [21], while TLR-3 resides intracel-
lularly in order to recognize nucleic acids delivered by a
cytoplasmic lipid raft protein, reftline, and depends
on intracellular trafficking differently from TLR-2 and
−4 [31,32]. LYST protein, as an intracellular trafficking
regulator whose function is reduced in individuals with
CHS, may have a more potent effect on highly regulated
cell surface expressed TLRs (e.g. TLR-2 and −4), than
intracellular and constitutive TLRs (e.g. TLR-3). It is
plausible to propose that skin fibroblasts constantly ex-
posed to exogenous viruses exhibit enhanced expression
of TLR-3 and its downstream signaling, which is affected
differently by LYST mutation compared to cell surface
TLRs and in turn leads to a hyperactive immune system
at baseline.
In contrast to the hyperactive expression at baseline,
skin fibroblasts from CHS individuals exhibit marked
hyporesponsiveness to LPS challenge, failing to alter
production of chemokines and cytokines including
CCL-7, IL-10, IL-15, IL-18, IL-1A, and IL-23A. Repeated
activation of TLR signaling results in a reduction in
the subsequent proinflammatory cytokine response,
a phenomenon known as TLR tolerance [33], as well
as changes in expression of other TLRs, known as
cross-tolerance [34]. In the case of CHS cells, gene
expression and correlation data suggest that constant
activation TLR-3 signaling potentially leads to elevated
expression of cytokines and chemokines, which in turn
represses the expression of TLR-4 and results in hypo-
sensitive immunogenic response. However, it remains
unclear why changes in TLR-2 did not correlate with
increased expression of other factors. TLR2 signaling
induction relies on heterodimerization with TLR-1 or
TLR-6 [35-37]. Significantly diminished expression ofTLR-1 in CHS cells may, explain in part, the complexity
of the altered TLR-2 expression.
Cytoplasmic membrane-associated TLRs signal through
two primary pathways, defined by the adaptor molecules
used to initiate each signal cascade. The classical MyD88-
dependent pathway relies on functioning cell surface
TLRs, is common to both TLR-2 and −4, and leads to
rapid activation of transcription factor κB (NF-κB) to
induce proinflammatory mediators such as TNF-α, IL-6
and COX-2 [17]. Our results support severely deficient
MyD88-dependent TLR signaling in CHS cells, based
on the observations of (1) decreased gene expression of
TLR-2, −4, and CD14; (2) attenuated cell surface expres-
sion of TLR-2 and −4; and (3) diminished response
under LPS challenge of MyD88-dependent proinflam-
matory mediators, e.g. IL-6 and CXCL2. Furthermore,
the presence of TLR-4 receptor complexes on the cytoplas-
mic membrane is maintained via continuous replenish-
ment of TLR-4 from intracellular compartments including
the Golgi apparatus and endosomes, which is a process
that is governed by small GTPase and MD-2 [22,38].
CHS skin fibroblasts exhibited enhanced expression of
MD-2, suggesting a compensatory mechanism that min-
imizes alterations in cytoplasmic TLR-4 protein in the
face of reduced TLR-4 expression. It will be important
to investigate how LYST affects interactions between
TLR4 and MD-2, in order to modulate cell surface
localization of TLR-4.
In addition to MyD88-dependent TLR signaling from
the cell membrane, internalization of TLRs can facilitate a
second signaling pathway that employs a distinct set of
sorting-signaling adaptors, called the MyD88-independent
pathway [17]. Although TLR-2 and −4 share some of the
MyD88-independent pathway adaptors, signaling activa-
tion of this pathway has different consequences for intra-
cellular trafficking of TLR-2 versus TLR-4. Internalization
of TLR-4, governed by the small GTPase, Rab11a, is ne-
cessary to induce MyD88-independent signaling [20]
while internalization of TLR-2 is not necessary for
signaling [39]. This difference may underlie the discrep-
ancy in how LYST mutations affect TLR-2 and TLR-4 in
CHS cells. In addition, internalization also results in the
TLR recycling through ubiquitination [21]. Since TLR-2
and TLR-4 differ in their mechanism of ubiquitination
[40,41], incorrect trafficking may lead to severe deple-
tion of TLR-2, but not TLR-4, in CHS cells. Future
studies elucidating this mechanism will provide insight
into how LYST contributes to TLR-2 and −4 functions
and recycling.
To the best of our knowledge, the results reported
here demonstrate for the first time the altered expres-
sion and localization of TLRs in cells obtained from
CHS subjects, and emphasize the importance for under-
standing the mechanism by which lysosome recycling
Wang et al. Orphanet Journal of Rare Diseases  (2014) 9:212 Page 10 of 11regulates TLR-mediated inflammatory signaling, and
immune function in a broader sense. Clinical features
resulting from LYST mutations in CHS have much
in common with immunodeficiencies caused by TLR
signaling defects, such as conditions caused by auto-
somal recessive mutations in TLR adapters, IRAK-4 and
MyD88 (OMIM# 610799, 607676, 612260). Like muta-
tions in LYST, reduced function of IRAK-4 and MyD88
results in selective impairment of cell responsiveness to
TLRs other than TLR-3 [42], and limited presence of
IL-6 protein when exposed to TLR agonists [43]. These
conditions feature noninvasive pyogenic bacterial infec-
tions affecting skin and upper respiratory tract, with
occasional periodontal disease [43]. However, patients
with MyD-88 and IRAK-4 deficiency show no impaired
defense against viral infections [43], due to their normal
functional natural killer cells [43] as well as their retained
ability to signal through TLR-3/-7/-9 and other non-TLR
viral receptors [44]. In contrast, patients with the classical
CHS phenotype develop life-threatening haemophagocytic
lymphohisticytosis following infections with viruses [5],
which may result from dysfunctional natural killer cells
lacking cytotoxic activities [45,46] as well as defective
trafficking in TLR-3/-7/-9 signaling.Conclusions
Taken together, these findings underscore that intracel-
lular vesicle trafficking is essential for normal immune
function. Loss of expression or proper localization of
TLR-2 and −4, together with the lack of response of cell
production of pro-inflammatory cytokines, leads to exac-
erbated bacterial burden and delayed clearance. A better
understanding of mechanisms governing local inflamma-
tory mechanisms may inform strategies for the manage-
ment of skin lesions burdened by excessive inflammation,
in CHS and other conditions of immunodeficiency.
Abbreviations
BCL6: B-cell CLL/lymphoma 6; BMT: Bone marrow transplant; C3AR1: Complement
component 3a receptor 1; CCL: Chemokine (C-C motif) ligand; CCR: Chemokine
(C-C motif) receptor; CD14: Cluster of differentiation 14; CEBPB: CCAAT/enhancer
binding protein (C/EBP), beta; CHS: Chediak-Higashi syndrome; Ctrl: Control;
COX-2: Cyclooxygenase-2; CSF1: Colony stimulating factor 1 (macrophage) CXCL,
Chemokine (C-X-C motif) ligand; CXCR: Chemokine (C-X-C motif) receptor;
DMEM: Dulbecco modified Eagle medium; FBS: Fetal bovine serum; IL: Interleukin;
IRAK: Interleukin-1 receptor-associated kinase; LPS: Lipopolysaccharide;
LTB: Lymphotoxin beta (TNF superfamily, member 3); LY96: Lymphocyte
antigen 96, also known as MD-2; LYST: Lysosomal trafficking regulator;
MD-2: Myeloid differentiation factor-2; MyD-88: Myeloid differentiation
primary response gene 88; NFKB1: Nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1; OCA: Oculocutaneous albinism;
PFA: Paraformaldehyde; Rab: Ras superfamily of monomeric G proteins;
RIPK2: Receptor-interacting serine-threonine kinase 2; SDS-PAGE: Sodium
dodecyl sulfate-Polyacrylamide gel electrophoresis; SELE: Selectin E;
TLR: Toll-like receptor; TNF: Tumor necrosis factor.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
LW and KRK co-drafted the manuscript. LW, KRK, FHN and ABT carried out
the clinical work and performed the gene expression analysis. FHN and LW
carried out protein extraction, Western blots and ELISA. ARC and JCR designed
and performed the immunofluorescence and membrane staining. BLF, MJS and
WJI provided advice on experimental design, and critically read and revised the
manuscript. MJS and WJI contributed clinical background and supervised the
study. LW, KRK, FHN and ARC participated in the design of the study and
performed the statistical analysis. All authors read and approved the final
manuscript.Acknowledgments
This research was supported by the Intramural Research Program of NIAMS
(LW, KRK, FHN, BLF, ABT, MJS) and NHGRI (ARC, JCR and WJI) of the NIH. The
authors acknowledge Dr. Samuel Black (University of Massachusetts at Amherst),
Dr. Richard Darveau (University of Washington), and Dr. Vivek Thumbigere-Math
(NIAMS/NIH, Bethesda, MD) for scientific advice, and Mudita Patel (NIAMS/NIH,
Bethesda, MD) for technique assistance.
Author details
1NIH/NIAMS - National Institute of Arthritis and Musculoskeletal and Skin
Diseases, Bethesda, MD, USA. 2University of Campinas - Piracicaba Dental
School, Piracicaba, Sao Paulo, Brazil. 3NIH/NHGRI - National Human Genome
Research Institute, Bethesda, MD, USA.
Received: 13 August 2014 Accepted: 10 December 2014
References
1. Introne W, Boissy RE, Gahl WA: Clinical, molecular, and cell biological
aspects of Chediak-Higashi syndrome. Mol Genet Metab 1999,
68(2):283–303.
2. Kaplan J, De Domenico I, Ward DM: Chediak-Higashi syndrome. Curr Opin
Hematol 2008, 15(1):22–29.
3. Roy A, Kar R, Basu D, Srivani S, Badhe BA: Clinico-hematological profile of
Chediak-Higashi syndrome: experience from a tertiary care center in
south India. Indian J Pathol Microbiol 2011, 54(3):547–551.
4. Armitage GC: Development of a classification system for periodontal
diseases and conditions. Ann Periodontol 1999, 4(1):1–6.
5. Lozano ML, Rivera J, Sanchez-Guiu I, Vicente V: Towards the targeted
management of Chediak-Higashi syndrome. Orphanet J Rare Dis 2014,
9:132.
6. Zhao H, Boissy YL, Abdel-Malek Z, King RA, Nordlund JJ, Boissy RE: On the
analysis of the pathophysiology of Chediak-Higashi syndrome. Defects
expressed by cultured melanocytes. Lab Invest 1994, 71(1):25–34.
7. Nagle DL, Karim MA, Woolf EA, Holmgren L, Bork P, Misumi DJ, McGrail SH,
Dussault BJ Jr, Perou CM, Boissy RE, Duyk GM, Spritz RA, Moore KJ:
Identification and mutation analysis of the complete gene for
Chediak-Higashi syndrome. Nat Genet 1996, 14(3):307–311.
8. Jones KL, Stewart RM, Fowler M, Fukuda M, Holcombe RF: Chediak-Higashi
lymphoblastoid cell lines: granule characteristics and expression of
lysosome-associated membrane proteins. Clin Immunol Immunopathol
1992, 65(3):219–226.
9. Durchfort N, Verhoef S, Vaughn MB, Shrestha R, Adam D, Kaplan J, Ward
DM: The enlarged lysosomes in beige j cells result from decreased
lysosome fission and not increased lysosome fusion. Traffic 2012,
13(1):108–119.
10. Stossel TP, Root RK, Vaughan M: Phagocytosis in chronic granulomatous
disease and the Chediak-Higashi syndrome. N Engl J Med 1972,
286(3):120–123.
11. Wang JW, Howson J, Haller E, Kerr WG: Identification of a novel
lipopolysaccharide-inducible gene with key features of both A kinase
anchor proteins and chs1/beige proteins. J Immunol 2001,
166(7):4586–4595.
12. Boxer LA, Smolen JE: Neutrophil granule constituents and their release in
health and disease. Hematol Oncol Clin North Am 1988, 2(1):101–134.
13. Ganz T, Metcalf JA, Gallin JI, Boxer LA, Lehrer RI: Microbicidal/cytotoxic
proteins of neutrophils are deficient in two disorders: Chediak-Higashi
syndrome and “specific” granule deficiency. J Clin Invest 1988,
82(2):552–556.
Wang et al. Orphanet Journal of Rare Diseases  (2014) 9:212 Page 11 of 1114. Jordana M, Sarnstrand B, Sime PJ, Ramis I: Immune-inflammatory functions
of fibroblasts. Eur Respir J 1994, 7(12):2212–2222.
15. Newton K, Dixit VM: Signaling in innate immunity and inflammation.
Cold Spring Harbor perspectives in biology 2012, 4(3):a006049.
16. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA: The fibroblast: sentinel
cell and local immune modulator in tumor tissue. Int J Cancer 2004,
108(2):173–180.
17. O'Neill LA, Golenbock D, Bowie AG: The history of Toll-like
receptors - redefining innate immunity. Nat Rev Immunol 2013,
13(6):453–460.
18. Wang PL, Ohura K: Porphyromonas gingivalis lipopolysaccharide signaling in
gingival fibroblasts-CD14 and Toll-like receptors. Crit Rev Oral Biol Med 2002,
13(2):132–142.
19. Sanjuan MA, Milasta S, Green DR: Toll-like receptor signaling in the
lysosomal pathways. Immunol Rev 2009, 227(1):203–220.
20. Husebye H, Aune MH, Stenvik J, Samstad E, Skjeldal F, Halaas O, Nilsen NJ,
Stenmark H, Latz E, Lien E, Mollnes TE, Bakke O, Espevik T: The Rab11a
GTPase controls Toll-like receptor 4-induced activation of interferon
regulatory factor-3 on phagosomes. Immunity 2010, 33(4):583–596.
21. McGettrick AF, O'Neill LA: Localisation and trafficking of Toll-like receptors:
an important mode of regulation. Curr Opin Immunol 2010, 22(1):20–27.
22. Wang D, Lou J, Ouyang C, Chen W, Liu Y, Liu X, Cao X, Wang J, Lu L:
Ras-related protein Rab10 facilitates TLR4 signaling by promoting
replenishment of TLR4 onto the plasma membrane. Proc Natl Acad Sci
U S A 2010, 107(31):13806–13811.
23. Nociti FH Jr, Foster BL, Tran AB, Dunn D, Presland RB, Wang L, Bhattacharyya
N, Collins MT, Somerman MJ: Vitamin D represses dentin matrix protein 1
in cementoblasts and osteocytes. J Dent Res 2014, 93(2):148–154.
24. Chen B, Tsui S, Smith TJ: IL-1 beta induces IL-6 expression in human
orbital fibroblasts: identification of an anatomic-site specific phenotypic
attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005,
175(2):1310–1319.
25. Hatakeyama J, Tamai R, Sugiyama A, Akashi S, Sugawara S, Takada H:
Contrasting responses of human gingival and periodontal ligament
fibroblasts to bacterial cell-surface components through the CD14/Toll-like
receptor system. Oral Microbiol Immunol 2003, 18(1):14–23.
26. Kjeldsen L, Calafat J, Borregaard N: Giant granules of neutrophils in
Chediak-Higashi syndrome are derived from azurophil granules but not
from specific and gelatinase granules. J Leukoc Biol 1998, 64(1):72–77.
27. White JG, Clawson CC: The Chediak-Higashi syndrome; the nature of the
giant neutrophil granules and their interactions with cytoplasm and
foreign particulates. I. Progressive enlargement of the massive inclusions
in mature neutrophils. II. Manifestations of cytoplasmic injury and
sequestration. III. Interactions between giant organelles and foreign
particulates. Am J Pathol 1980, 98(1):151–196.
28. Mahoney KH, Morse SS, Morahan PS: Macrophage functions in beige
(Chediak-Higashi syndrome) mice. Cancer Res 1980, 40(11):3934–3939.
29. Argyle JC, Kjeldsberg CR, Marty J, Shigeoka AO, Hill HR: T-cell lymphoma
and the Chediak-Higashi syndrome. Blood 1982, 60(3):672–676.
30. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD,
Bugelski PJ, Murray LA, Marsters PA, Bunting RA, Flavell RA, Alexopoulou L,
San Mateo LR, Griswold DE, Sarisky RT, Mbow ML, Das AM: Long-term
activation of TLR3 by poly (I:C) induces inflammation and impairs lung
function in mice. Respir Res 2009, 10:43.
31. Tatematsu M, Nishikawa F, Seya T, Matsumoto M: Toll-like receptor 3
recognizes incomplete stem structures in single-stranded viral RNA.
Nat Commun 2013, 4:1833.
32. Watanabe A, Tatematsu M, Saeki K, Shibata S, Shime H, Yoshimura A,
Obuse C, Seya T, Matsumoto M: Raftlin is involved in the nucleocapture
complex to induce poly(I:C)-mediated TLR3 activation. J Biol Chem 2011,
286(12):10702–10711.
33. Broad A, Kirby JA, Jones DE, Applied I, Transplantation Research G: Toll-like
receptor interactions: tolerance of MyD88-dependent cytokines but
enhancement of MyD88-independent interferon-beta production.
Immunology 2007, 120(1):103–111.
34. Peroval MY, Boyd AC, Young JR, Smith AL: A critical role for MAPK
signalling pathways in the transcriptional regulation of toll like
receptors. PLoS One 2013, 8(2):e51243.
35. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-Beckmann
U, Roschmann K, Jung G, Wiesmuller KH, Ulmer AJ: Heterodimerization ofTLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to
differential signaling. J Leukoc Biol 2008, 83(3):692–701.
36. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO: Crystal
structure of the TLR1-TLR2 heterodimer induced by binding of a
tri-acylated lipopeptide. Cell 2007, 130(6):1071–1082.
37. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL,
Akira S: Cutting edge: role of Toll-like receptor 1 in mediating immune
response to microbial lipoproteins. J Immunol 2002, 169(1):10–14.
38. Calvano JE, Agnese DM, Um JY, Goshima M, Singhal R, Coyle SM, Reddell
MT, Kumar A, Calvano SE, Lowry SF: Modulation of the lipopolysaccharide
receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic
inflammatory response syndrome-positive patients with and without
infection: relationship to tolerance. Shock 2003, 20(5):415–419.
39. Triantafilou M, Manukyan M, Mackie A, Morath S, Hartung T, Heine H,
Triantafilou K: Lipoteichoic acid and toll-like receptor 2 internalization
and targeting to the Golgi are lipid raft-dependent. J Biol Chem 2004,
279(39):40882–40889.
40. Chuang TH, Ulevitch RJ: Triad3A, an E3 ubiquitin-protein ligase regulating
Toll-like receptors. Nat Immunol 2004, 5(5):495–502.
41. Nakamura M, Watanabe J, Watanabe N: Ubiquitin-like protein MNSFbeta
regulates TLR-2-mediated signal transduction. Mol Cell Biochem 2012,
364(1–2):39–43.
42. Picard C, Casanova JL, Puel A: Infectious diseases in patients with IRAK-4,
MyD88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 2011,
24(3):490–497.
43. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, Arkwright PD,
McDonald D, Geha RS, Takada H, Krause JC, Creech CB, Ku CL, Ehl S, Maródi
L, Al-Muhsen S, Al-Hajjar S, Al-Ghonaium A, Day-Good NK, Holland SM, Gallin
JI, Chapel H, Speert DP, Rodriguez-Gallego C, Colino E, Garty BZ, Roifman C,
Hara T, Yoshikawa H, Nonoyama S, Domachowske J, et al: Clinical features
and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine
2010, 89(6):403–425.
44. Pennini ME, Perkins DJ, Salazar AM, Lipsky M, Vogel SN: Complete
dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling
pathways underlies decreased cytokine production and increased
susceptibility to Streptococcus pneumoniae infection in IRAK4
kinase-inactive mice. J Immunol 2013, 190(1):307–316.
45. Nair MP, Gray RH, Boxer LA, Schwartz SA: Deficiency of inducible suppressor
cell activity in the Chediak-Higashi syndrome. Am J Hematol 1987,
26(1):55–66.
46. Targan SR, Oseas R: The “lazy” NK cells of Chediak-Higashi syndrome.
J Immunol 1983, 130(6):2671–2674.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
